医学
FGF21型
内科学
随机对照试验
成纤维细胞生长因子
受体
作者
Rohit Loomba,Arun J. Sanyal,Kris V. Kowdley,Deepak L. Bhatt,Naim Alkhouri,Juan P. Frías,Pierre Bédossa,Stephen A. Harrison,Donald J. Lazas,Robert J. Barish,Mildred D. Gottwald,Shibao Feng,Germaine D. Agollah,Cynthia L. Hartsfield,Hank Mansbach,Maya Margalit,Manal F. Abdelmalek
标识
DOI：10.1056/nejmoa2304286
摘要
Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The efficacy and safety of pegozafermin in patients with biopsy-proven noncirrhotic NASH are not well established.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
lzx
GingerF
昏睡的蟠桃
孙燕
SYLH
学术达人
herococa
pcr163
我是站长才怪
Rubby
风清扬
zho
clientprogram
Billy
Sandy
nenoaowu
andrele
Michael
鸣笛
YifanWang
皖公网安备34019202002308
